Richmond

Founded in 2001, Richmond Pharmacology is a leading Contract Research Organisation (CRO) with a heritage in first-in-human and adaptive clinical trials. It has conducted around 20% of all UK Phase I studies and ran the first clinical trial in which a CRISPR therapy was delivered through the bloodstream to edit genes inside the human body. 

Today, Richmond supports global pharmaceutical, biotech, and genetic engineering partners, including several top 10 pharma companies, in advancing next-generation therapies. In 2020, it established the Richmond Research Institute to expand understanding of under-researched diseases.